Rosalinda Madonna

List of Publications by Citations

140 papers	4,187 citations	36 h-index	59 g-index
153 ext. papers	5,093 ext. citations	6.1 avg, IF	5.62 L-index

#	Paper	IF	Citations
140	Novel targets and future strategies for acute cardioprotection: Position Paper of the European Society of Cardiology Working Group on Cellular Biology of the Heart. *Cardiovascular Research*, **2017**, 113, 564-585	9.9	206
139	Extracellular vesicles in diagnostics and therapy of the ischaemic heart: Position Paper from the Working Group on Cellular Biology of the Heart of the European Society of Cardiology. *Cardiovascular Research*, **2018**, 114, 19-34	9.9	198
138	Translating cardioprotection for patient benefit: position paper from the Working Group of Cellular Biology of the Heart of the European Society of Cardiology. *Cardiovascular Research*, **2013**, 98, 7-27	9.9	172
137	Position Paper of the European Society of Cardiology Working Group Cellular Biology of the Heart: cell-based therapies for myocardial repair and regeneration in ischemic heart disease and heart failure. *European Heart Journal*, **2016**, 37, 1789-98	9.5	163
136	Adipose tissue-derived stem cells: characterization and potential for cardiovascular repair. *Arteriosclerosis, Thrombosis, and Vascular Biology*, **2009**, 29, 1723-9	9.4	126
135	ESC working group cellular biology of the heart: position paper: improving the preclinical assessment of novel cardioprotective therapies. *Cardiovascular Research*, **2014**, 104, 399-411	9.9	108
134	Cellular and molecular mechanisms of vascular injury in diabetes--part I: pathways of vascular disease in diabetes. *Vascular Pharmacology*, **2011**, 54, 68-74	5.9	108
133	n-3 fatty acids in the treatment of diabetic patients: biological rationale and clinical data. *Diabetes Care*, **2007**, 30, 1012-26	14.6	93
132	Nutritional mechanisms that influence cardiovascular disease. *American Journal of Clinical Nutrition*, **2006**, 83, 421S-426S	7	92
131	Global position paper on cardiovascular regenerative medicine. *European Heart Journal*, **2017**, 38, 2532-2546	9.9	90
130	Epigenomic and transcriptomic approaches in the post-genomic era: path to novel targets for diagnosis and therapy of the ischaemic heart? Position Paper of the European Society of Cardiology Working Group on Cellular Biology of the Heart. *Cardiovascular Research*, **2017**, 113, 725-736	9.9	85
129	Left ventricular assist devices and gastrointestinal bleeding: a narrative review of case reports and case series. *Clinical Cardiology*, **2013**, 36, 190-200	3.3	83
128	ESC Joint Working Groups on Cardiovascular Surgery and the Cellular Biology of the Heart Position Paper: Perioperative myocardial injury and infarction in patients undergoing coronary artery bypass graft surgery. *European Heart Journal*, **2017**, 38, 2392-2407	9.5	75
127	Antineoplastic Drug-Induced Cardiotoxicity: A Redox Perspective. *Frontiers in Physiology*, **2018**, 9, 167	4.6	74
126	Simvastatin attenuates expression of cytokine-inducible nitric-oxide synthase in embryonic cardiac myoblasts. *Journal of Biological Chemistry*, **2005**, 280, 13503-11	5.4	73
125	From Molecular Mechanisms to Clinical Management of Antineoplastic Drug-Induced Cardiovascular Toxicity: A Translational Overview. *Antioxidants and Redox Signaling*, **2019**, 30, 2110-2153	8.4	73
124	Transplantation of mesenchymal cells rejuvenated by the overexpression of telomerase and myocardin promotes revascularization and tissue repair in a murine model of hindlimb ischemia. *Circulation Research*, **2013**, 113, 902-14	15.7	72

123	Age-dependent impairment of number and angiogenic potential of adipose tissue-derived progenitor cells. *European Journal of Clinical Investigation*, **2011**, 41, 126-33	4.6	70
122	Diabetic microangiopathy: Pathogenetic insights and novel therapeutic approaches. *Vascular Pharmacology*, **2017**, 90, 1-7	5.9	64
121	Novel therapeutic strategies for cardioprotection. *Pharmacology & Therapeutics*, **2014**, 144, 60-70	13.9	57
120	Antiarrhythmic effects of omega-3 fatty acids: from epidemiology to bedside. *American Heart Journal*, **2003**, 146, 420-30	4.9	57
119	High glucose-induced hyperosmolarity contributes to COX-2 expression and angiogenesis: implications for diabetic retinopathy. *Cardiovascular Diabetology*, **2016**, 15, 18	8.7	53
118	Anticancer therapy-induced vascular toxicity: VEGF inhibition and beyond. *International Journal of Cardiology*, **2017**, 227, 11-17	3.2	52
117	ESC Working Group on Cellular Biology of the Heart: position paper for Cardiovascular Research: tissue engineering strategies combined with cell therapies for cardiac repair in ischaemic heart disease and heart failure. *Cardiovascular Research*, **2019**, 115, 488-500	9.9	51
116	In vitro neovasculogenic potential of resident adipose tissue precursors. *American Journal of Physiology - Cell Physiology*, **2008**, 295, C1271-80	5.4	51
115	Hepatocyte growth factor/Met gene transfer in cardiac stem cells--potential for cardiac repair. *Basic Research in Cardiology*, **2010**, 105, 443-52	11.8	49
114	Adipose tissue: a new source for cardiovascular repair. *Journal of Cardiovascular Medicine*, **2010**, 11, 71-80	2.9	48
113	Effects of omega-3 fatty acids on cytokines and adhesion molecules. *Current Atherosclerosis Reports* , **2004**, 6, 485-91	6	47
112	The emerging role of Notch pathway in ageing: Focus on the related mechanisms in age-related diseases. *Ageing Research Reviews*, **2016**, 29, 50-65	12	46
111	Transplantation of adipose tissue mesenchymal cells conjugated with VEGF-releasing microcarriers promotes repair in murine myocardial infarction. *Cardiovascular Research*, **2015**, 108, 39-49	9.9	45
110	Glycaemic control in acute coronary syndromes: prognostic value and therapeutic options. *European Heart Journal*, **2010**, 31, 1557-64	9.5	44
109	Circulating endothelial progenitor cells: Do they live up to their name?. *Vascular Pharmacology*, **2015**, 67-69, 2-5	5.9	43
108	Cellular and molecular mechanisms of vascular injury in diabetes--part II: cellular mechanisms and therapeutic targets. *Vascular Pharmacology*, **2011**, 54, 75-9	5.9	41
107	Myocardin a enhances telomerase activities in adipose tissue mesenchymal cells and embryonic stem cells undergoing cardiovascular myogenic differentiation. *Stem Cells*, **2008**, 26, 202-11	5.8	40
106	A recommended practical approach to the management of anthracycline-based chemotherapy cardiotoxicity: an opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology. *Journal of Cardiovascular Medicine*, **2016**, 17 Suppl 1, S84-92	1.9	39

105	Hepatocyte growth factor: molecular biomarker and player in cardioprotection and cardiovascular regeneration. *Thrombosis and Haemostasis*, **2012**, 107, 656-61	7	38
104	Loss of Smooth Muscle Actin Leads to NF-B-Dependent Increased Sensitivity to Angiotensin II in Smooth Muscle Cells and Aortic Enlargement. *Circulation Research*, **2017**, 120, 1903-1915	15.7	35
103	Current views on anthracycline cardiotoxicity. *Heart Failure Reviews*, **2016**, 21, 621-34	5	35
102	Biologic function and clinical potential of telomerase and associated proteins in cardiovascular tissue repair and regeneration. *European Heart Journal*, **2011**, 32, 1190-6	9.5	35
101	Functional Genomics of Cardioprotection by Ischemic Conditioning and the Influence of Comorbid Conditions: Implications in Target Identification. *Current Drug Targets*, **2015**, 16, 904-11	3	35
100	Relevance of new drug discovery to reduce NF-B activation in cardiovascular disease. *Vascular Pharmacology*, **2012**, 57, 41-7	5.9	34
99	Toll-like receptor-4 signaling pathway in aorta aging and diseases: "its double nature". *Journal of Molecular and Cellular Cardiology*, **2017**, 110, 38-53	5.8	33
98	Improving the preclinical models for the study of chemotherapy-induced cardiotoxicity: a Position Paper of the Italian Working Group on Drug Cardiotoxicity and Cardioprotection. *Heart Failure Reviews*, **2015**, 20, 621-31	5	32
97	Innate and adaptive immunity in atherosclerosis. *Vascular Pharmacology*, **2018**, 107, 67-67	5.9	32
96	Cellular and molecular basis of the imbalance between vascular damage and repair in ageing and age-related diseases: As biomarkers and targets for new treatments. *Mechanisms of Ageing and Development*, **2016**, 159, 22-30	5.6	31
95	Prolonged exposure to high insulin impairs the endothelial PI3-kinase/Akt/nitric oxide signalling. *Thrombosis and Haemostasis*, **2009**, 101, 345-350	7	31
94	A recommended practical approach to the management of target therapy and angiogenesis inhibitors cardiotoxicity: an opinion paper of the working group on drug cardiotoxicity and cardioprotection, Italian Society of Cardiology. *Journal of Cardiovascular Medicine*, **2016**, 17 Suppl 1, S93-S104	1.9	31
93	Impact of Sex Differences and Diabetes on Coronary Atherosclerosis and Ischemic Heart Disease. *Journal of Clinical Medicine*, **2019**, 8,	5.1	28
92	The epicardial adipose tissue and the coronary arteries: dangerous liaisons. *Cardiovascular Research* , **2019**, 115, 1013-1025	9.9	25
91	Cardioprotection by gene therapy: A review paper on behalf of the Working Group on Drug Cardiotoxicity and Cardioprotection of the Italian Society of Cardiology. *International Journal of Cardiology*, **2015**, 191, 203-10	3.2	25
90	Diabetic macroangiopathy: Pathogenetic insights and novel therapeutic approaches with focus on high glucose-mediated vascular damage. *Vascular Pharmacology*, **2018**,	5.9	25
89	High glucose-induced hyperosmolarity impacts proliferation, cytoskeleton remodeling and migration of human induced pluripotent stem cells via aquaporin-1. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **2014**, 1842, 2266-75	6.9	25
88	Recent developments in cardiovascular stem cells. *Circulation Research*, **2014**, 115, e71-8	15.7	25

87	Insulin potentiates cytokine-induced VCAM-1 expression in human endothelial cells. *Biochimica Et Biophysica Acta - Molecular Basis of Disease*, **2008**, 1782, 511-6	6.9	25
86	Pathophysiology of anthracycline cardiotoxicity. *Journal of Cardiovascular Medicine*, **2016**, 17 Suppl 1, S3-S11	1.9	25
85	Sex differences in anthracycline-induced cardiotoxicity: the benefits of estrogens. *Heart Failure Reviews*, **2019**, 24, 915-925	5	24
84	Improving translational research in sex-specific effects of comorbidities and risk factors in ischaemic heart disease and cardioprotection: position paper and recommendations of the ESC Working Group on Cellular Biology of the Heart. *Cardiovascular Research*, **2021**, 117, 367-385	9.9	24
83	Human-induced pluripotent stem cells: in quest of clinical applications. *Molecular Biotechnology*, **2012**, 52, 193-203	3	23
82	Stem cells and growth factor delivery systems for cardiovascular disease. *Journal of Biotechnology*, **2011**, 154, 291-7	3.7	23
81	Nitroso-Redox Balance and Modulation of Basal Myocardial Function: An Update from the Italian Society of Cardiovascular Research (SIRC). *Current Drug Targets*, **2015**, 16, 895-903	3	23
80	Novel insights in pathophysiology of antiblastic drugs-induced cardiotoxicity and cardioprotection. *Journal of Cardiovascular Medicine*, **2016**, 17 Suppl 1, S76-83	1.9	22
79	Omega-3 fatty acids attenuate constitutive and insulin-induced CD36 expression through a suppression of PPAR activity in microvascular endothelial cells. *Thrombosis and Haemostasis*, **2011**, 106, 500-10	7	22
78	Effect of High-Dose Atorvastatin Reload on the Release of Endothelial Progenitor Cells in Patients on Long-Term Statin Treatment Who Underwent Percutaneous Coronary Intervention (from the ARMYDA-EPC Study). *American Journal of Cardiology*, **2016**, 117, 165-71	3	21
77	Perspectives on Directions and Priorities for Future Preclinical Studies in Regenerative Medicine. *Circulation Research*, **2019**, 124, 938-951	15.7	20
76	Co-activation of nuclear factor-B and myocardin/serum response factor conveys the hypertrophy signal of high insulin levels in cardiac myoblasts. *Journal of Biological Chemistry*, **2014**, 289, 19585-98	5.4	19
75	VEGF receptor switching in heart development and disease. *Cardiovascular Research*, **2009**, 84, 4-6	9.9	19
74	Non-coding RNAs: update on mechanisms and therapeutic targets from the ESC Working Groups of Myocardial Function and Cellular Biology of the Heart. *Cardiovascular Research*, **2020**, 116, 1805-1819	9.9	18
73	Preventing antiblastic drug-related cardiomyopathy: old and new therapeutic strategies. *Journal of Cardiovascular Medicine*, **2016**, 17 Suppl 1, S64-75	1.9	18
72	Pathways and Drugs in Pulmonary Arterial Hypertension - Focus on the Role of Endothelin Receptor Antagonists. *Cardiovascular Drugs and Therapy*, **2015**, 29, 469-79	3.9	17
71	Non-invasive in vivo detection of peripheral limb ischemia improvement in the rat after adipose tissue-derived stromal cell transplantation. *Circulation Journal*, **2012**, 76, 1517-25	2.9	17
70	Cardiac dysfunction in cancer patients: beyond direct cardiomyocyte damage of anticancer drugs: novel cardio-oncology insights from the joint 2019 meeting of the ESC Working Groups of Myocardial Function and Cellular Biology of the Heart. *Cardiovascular Research*, **2020**, 116, 1820-1834	9.9	17

69	Diagnostic and Prognostic Relevance of Red Blood Cell Distribution Width for Vascular Aging and Cardiovascular Diseases. *Rejuvenation Research*, **2019**, 22, 146-162	2.6	16
68	Cardiomyocyte ageing and cardioprotection: consensus document from the ESC working groups cell biology of the heart and myocardial function. *Cardiovascular Research*, **2020**, 116, 1835-1849	9.9	15
67	Cardiovascular imaging in the diagnosis and monitoring of cardiotoxicity: role of echocardiography. *Journal of Cardiovascular Medicine*, **2016**, 17 Suppl 1, S35-44	1.9	15
66	Perivascular fibrosis and the microvasculature of the heart. Still hidden secrets of pathophysiology?. *Vascular Pharmacology*, **2018**, 107, 78-78	5.9	14
65	Transplantation of mesenchymal cells improves peripheral limb ischemia in diabetic rats. *Molecular Biotechnology*, **2014**, 56, 438-48	3	14
64	Glucose metabolism, hyperosmotic stress, and reprogramming of somatic cells. *Molecular Biotechnology*, **2013**, 55, 169-78	3	14
63	Prognostically relevant periprocedural myocardial injury and infarction associated with percutaneous coronary interventions: a Consensus Document of the ESC Working Group on Cellular Biology of the Heart and European Association of Percutaneous Cardiovascular Interventions (EAPCI). *European Heart Journal*, **2021**, 42, 2630-2642	9.5	13
62	Developmental programming of adult haematopoiesis system. *Ageing Research Reviews*, **2019**, 54, 100918	11.8	12
61	Potential cardiac risk of immune-checkpoint blockade as anticancer treatment: What we know, what we do not know, and what we can do to prevent adverse effects. *Medicinal Research Reviews*, **2018**, 38, 1447-1468	14.4	12
60	Erythropoietin protects myocardin-expressing cardiac stem cells against cytotoxicity of tumor necrosis factor-alpha. *Experimental Cell Research*, **2009**, 315, 2921-8	4.2	12
59	Understanding the heart-brain axis response in COVID-19 patients: A suggestive perspective for therapeutic development. *Pharmacological Research*, **2021**, 168, 105581	10.2	12
58	Exogenous Nitric Oxide Protects Human Embryonic Stem Cell-Derived Cardiomyocytes against Ischemia/Reperfusion Injury. *Oxidative Medicine and Cellular Longevity*, **2016**, 2016, 4298945	6.7	12
57	Proteomic analysis of the secretome of adipose tissue-derived murine mesenchymal cells overexpressing telomerase and myocardin. *Journal of Molecular and Cellular Cardiology*, **2019**, 131, 171-186	5.8	11
56	Epigenetic regulation of insulin-like growth factor signaling: A novel insight into the pathophysiology of neonatal pulmonary hypertension. *Vascular Pharmacology*, **2015**, 73, 4-7	5.9	11
55	Impaired fasting plasma glucose and long-term cardiovascular risk: still a foggy relationship. *European Heart Journal*, **2010**, 31, 1159-62	9.5	11
54	Prolonged exposure to high insulin impairs the endothelial PI3-kinase/Akt/nitric oxide signalling. *Thrombosis and Haemostasis*, **2009**, 101, 345-50	7	11
53	Aquaporin-1 and sodium-hydrogen exchangers as pharmacological targets in diabetic atherosclerosis. *Current Drug Targets*, **2015**, 16, 361-5	3	10
52	"State-of-Art" paper of the Italian Working Group on Atherosclerosis: Preclinical assessment of early coronary atherosclerosis. *International Journal of Cardiology*, **2016**, 214, 442-7	3.2	10

51	Ponatinib Induces Vascular Toxicity through the Notch-1 Signaling Pathway. *Journal of Clinical Medicine*, **2020**, 9,	5.1	9
50	Simulated hyperglycemia impairs insulin signaling in endothelial cells through a hyperosmolar mechanism. *Vascular Pharmacology*, **2020**, 130, 106678	5.9	9
49	The acute impact of high-dose lipid-lowering treatment on endothelial progenitor cells in patients with coronary artery disease-The REMEDY-EPC early substudy. *PLoS ONE*, **2017**, 12, e0172800	3.7	9
48	Myocardin-A enhances expression of promyogenic genes without depressing telomerase activity in adipose tissue-derived mesenchymal stem cells. *International Journal of Cardiology*, **2013**, 167, 2912-21	3.2	9
47	Melatonin as a cardioprotective therapy following ST-segment elevation myocardial infarction: is it really promising? Reply. *Cardiovascular Research*, **2017**, 113, 1418-1419	9.9	9
46	MR angiography, MR imaging and proton MR spectroscopy in-vivo assessment of skeletal muscle ischemia in diabetic rats. *PLoS ONE*, **2012**, 7, e44752	3.7	9
45	Targeting phosphatidylinositol 3-kinase-Akt through hepatocyte growth factor for cardioprotection. *Journal of Cardiovascular Medicine*, **2013**, 14, 249-53	1.9	9
44	Nutrients and gene expression. *World Review of Nutrition and Dietetics*, **2004**, 93, 99-133	0.2	9
43	Empagliflozin reduces the senescence of cardiac stromal cells and improves cardiac function in a murine model of diabetes. *Journal of Cellular and Molecular Medicine*, **2020**, 24, 12331-12340	5.6	9
42	Epigenetic modulation of vascular diseases: Assessing the evidence and exploring the opportunities. *Vascular Pharmacology*, **2018**,	5.9	8
41	Multimodality imaging for pre-clinical assessment of Fabry's cardiomyopathy. *European Heart Journal Cardiovascular Imaging*, **2014**, 15, 1094-100	4.1	8
40	Prostacyclin improves transcoronary myocardial delivery of adipose tissue-derived stromal cells. *European Heart Journal*, **2006**, 27, 2054-61	9.5	8
39	COVID-19-related cardiac complications from clinical evidences to basic mechanisms: opinion paper of the ESC Working Group on Cellular Biology of the Heart. *Cardiovascular Research*, **2021**, 117, 2148-2160	9.9	8
38	Stimulating pro-reparative immune responses to prevent adverse cardiac remodelling: consensus document from the joint 2019 meeting of the ESC Working Groups of cellular biology of the heart and myocardial function. *Cardiovascular Research*, **2020**, 116, 1850-1862	9.9	7
37	Sodium-hydrogen exchangers (NHE) in human cardiovascular diseases: interfering strategies and their therapeutic applications. *Vascular Pharmacology*, **2013**, 59, 127-30	5.9	7
36	Immune cells in cardiac homeostasis and disease: emerging insights from novel technologies.. *European Heart Journal*, **2021**,	9.5	7
35	Stem Cell Aging and Age-Related Cardiovascular Disease: Perspectives of Treatment by Ex-vivo Stem Cell Rejuvenation. *Current Drug Targets*, **2015**, 16, 780-5	3	7
34	Insights into therapeutic products, preclinical research models, and clinical trials in cardiac regenerative and reparative medicine: where are we now and the way ahead. Current opinion paper of the ESC Working Group on Cardiovascular Regenerative and Reparative Medicine. *Cardiovascular Research*, **2021**, 117, 1428-1433	9.9	7

33	Long-term engraftment and angiogenic properties of lentivirally transduced adipose tissue-derived stromal cells. *Molecular Biotechnology*, **2013**, 54, 13-24	3	6
32	Simvastatin-enhanced expression of promyogenic nuclear factors and cardiomyogenesis of murine embryonic stem cells. *Vascular Pharmacology*, **2014**, 60, 8-16	5.9	5
31	Diagnóstico y prevención de la cardiotoxicidad inducida por fármacos antineoplásicos: de la imagen a las tecnologías «ómicas». *Revista Espanola De Cardiologia*, **2017**, 70, 576-582	1.5	5
30	Novel Strategies in the Treatment of Pulmonary Arterial Hypertension. *Current Drug Targets*, **2016**, 17, 817-23	3	5
29	Rosuvastatin for Reduction of Myocardial Damage during Coronary Angioplasty - the Remedy Trial. *Cardiovascular Drugs and Therapy*, **2016**, 30, 465-472	3.9	5
28	Co-expression of glycosylated aquaporin-1 and transcription factor NFAT5 contributes to aortic stiffness in diabetic and atherosclerosis-prone mice. *Journal of Cellular and Molecular Medicine*, **2020**, 24, 2857-2865	5.6	4
27	Aerobic exercise-related attenuation of arterial pulmonary hypertension: A right arrow targets the disease?. *Vascular Pharmacology*, **2016**, 87, 6-9	5.9	4
26	Early Diagnosis and Prediction of Anticancer Drug-induced Cardiotoxicity: From Cardiac Imaging to "Omics" Technologies. *Revista Espanola De Cardiologia (English Ed)*, **2017**, 70, 576-582	0.7	3
25	Transplantation of telomerase/myocardin-co-expressing mesenchymal cells in the mouse promotes myocardial revascularization and tissue repair. *Vascular Pharmacology*, **2020**, 135, 106807	5.9	3
24	Isolated Exercise-Induced Pulmonary Hypertension Associates with Higher Cardiovascular Risk in Scleroderma Patients. *Journal of Clinical Medicine*, **2020**, 9,	5.1	3
23	Animal models and animal-free innovations for cardiovascular research: current status and routes to be explored. Consensus document of the ESC working group on myocardial function and the ESC Working Group on Cellular Biology of the Heart.. *Cardiovascular Research*, **2022**,	9.9	3
22	Association of the European Society of Cardiology echocardiographic probability grading for pulmonary hypertension with short and mid-term clinical outcomes after heart valve surgery. *Vascular Pharmacology*, **2020**, 125-126, 106648	5.9	3
21	Electrical plasticity and cardioprotection in myocardial ischemia--role of selective sodium channel blockers. *Clinical Cardiology*, **2013**, 36, 255-61	3.3	2
20	Atherogenesis and Diabetes: Focus on Insulin Resistance and Hyperinsulinemia. *Revista Espanola De Cardiologia (English Ed)*, **2012**, 65, 309-313	0.7	2
19	Telomerase/myocardin expressing mesenchymal cells induce survival and cardiovascular markers in cardiac stromal cells undergoing ischaemia/reperfusion. *Journal of Cellular and Molecular Medicine*, **2021**, 25, 5381-5390	5.6	2
18	Exploring the mechanisms of action of gliflozines in heart failure and possible implications in pulmonary hypertension. *Vascular Pharmacology*, **2021**, 138, 106839	5.9	2
17	Exercise-induced pulmonary hypertension in HFpEF and HFrEF: Different pathophysiologic mechanism behind similar functional impairment.. *Vascular Pharmacology*, **2022**, 106978	5.9	2
16	Sex-related differential susceptibility to ponatinib cardiotoxicity and differential modulation of the Notch1 signalling pathway in a murine model.. *Journal of Cellular and Molecular Medicine*, **2022**,	5.6	1

List of Publications

15	Sodium-glucose cotransporter type 2 inhibitors prevent ponatinib-induced endothelial senescence and disfunction: A potential rescue strategy. *Vascular Pharmacology*, **2021**, 142, 106949	5.9	1
14	Connexin 43 and Connexin 26 Involvement in the Ponatinib-Induced Cardiomyopathy: Sex-Related Differences in a Murine Model. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	1
13	Anthracyclines and regional myocardial damage in breast cancer patients. A multicentre study from the Working Group on Drug Cardiotoxicity and Cardioprotection, Italian Society of Cardiology (SIC). *European Heart Journal Cardiovascular Imaging*, **2021**, 22, 406-415	4.1	1
12	Angiocrine endothelium: From physiology to atherosclerosis and cardiac repair.. *Vascular Pharmacology*, **2022**, 106993	5.9	1
11	Pulse wave velocity in white coat and masked hypertension. *Journal of Clinical Hypertension*, **2020**, 22, 812-813	2.3	0
10	The Nutrigenetics of Cardiovascular Disease **2020**, 355-360		0
9	Exercise-induced pulmonary hypertension in HIV patients: Association with poor clinical and immunological status. *Vascular Pharmacology*, **2021**, 139, 106888	5.9	0
8	Is it the time of seno-therapeutics application in cardiovascular pathological conditions related to ageing?. *Current Research in Pharmacology and Drug Discovery*, **2021**, 2, 100027	3	0
7	Pharmacogenomics and circadian rhythms as mediators of cardiovascular drug-drug interactions.. *Current Research in Pharmacology and Drug Discovery*, **2021**, 2, 100025	3	0
6	Multi-Target Drugs for Blood Cancer in the Elderly: Implications of Damage and Repair in the Cardiovascular Toxicity.. *Frontiers in Physiology*, **2021**, 12, 792751	4.6	0
5	Stem Cell Therapies for Cardiac Regeneration: Current Burden Future Directions. *Pancreatic Islet Biology*, **2016**, 191-196	0.4	
4	Induced Pluripotent Stem Cells for Cardiac Regeneration. *Pancreatic Islet Biology*, **2016**, 31-43	0.4	
3	Prevention and Clinical Management of Cardiovascular Damage Induced by Anticancer Drugs: Need for Early Biomarkers and Cardio- and Vasculoprotection in Personalized Therapy. *Current Clinical Pathology*, **2019**, 183-204	0.1	
2	The Fourth European-South African Cardiovascular Research Workshop. *European Heart Journal*, **2020**, 41, 203-204	9.5	
1	The ESC Working Group on Cellular Biology of the Heart. *European Heart Journal*, **2020**, 41, 2614-2616	9.5	